*	OR T6 T7 T8 T9 T10
R1	AND Arg1:T6 Arg2:T11	
R2	Has_qualifier Arg1:T13 Arg2:T14	
R3	Has_index Arg1:T15 Arg2:T16	
R4	Has_temporal Arg1:T13 Arg2:T15	
R5	Has_qualifier Arg1:T21 Arg2:T25	
R6	Has_negation Arg1:T21 Arg2:T24	
*	OR T18 T19 T20
R8	AND Arg1:T19 Arg2:T21	
R10	Has_negation Arg1:T27 Arg2:T23	
R9	Has_multiplier Arg1:T22 Arg2:T28	
R7	Has_qualifier Arg1:T18 Arg2:T17	
*	OR T19 T22
R11	Has_qualifier Arg1:T32 Arg2:T33	
*	OR T31 T32
*	OR T38 T39 T40
*	OR T47 T46
R12	Has_qualifier Arg1:T45 Arg2:T47	
*	OR T34 T44 T43 T42 T37 T36 T35 T45
R13	Has_qualifier Arg1:T37 Arg2:T38	
R14	Subsumes Arg1:T32 Arg2:T34	
R15	AND Arg1:T50 Arg2:T51	
R16	Has_value Arg1:T53 Arg2:T54	
R17	AND Arg1:T52 Arg2:T53	
R18	Has_value Arg1:T56 Arg2:T57	
R19	AND Arg1:T55 Arg2:T56	
*	OR T60 T61 T62 T63
R20	Subsumes Arg1:T58 Arg2:T60	
R21	Has_value Arg1:T65 Arg2:T66	
R22	AND Arg1:T19 Arg2:T20	
T1	Pregnancy_considerations 0 145	Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation
T2	Pregnancy_considerations 147 288	Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond
T3	Non-query-able 290 501	History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
T4	Competing_trial 503 608	Participation in another clinical trial during the present clinical trial or within the last three months
T5	Informed_consent 610 721	Medical or psychological condition that would not permit completion of the trial or signing of informed consent
T6	Drug 732 750	fibrinolytic agent
T7	Procedure 752 774	surgical thrombectomy,
T8	Procedure 810 829	thrombus aspiration
T9	Procedure 810 818;833 838	thrombus lysis
T10	Procedure 852 863	cava filter
T11	Condition 894 896	PE
T13	Drug 939 952	anticoagulant
T14	Qualifier 917 932	therapeutically
T15	Temporal 957 994	more than 48 hours prior to enrolment
T16	Reference_point 985 994	enrolment
T17	Qualifier 1005 1014	long-term
T18	Drug 1032 1060	low molecular weight heparin
T19	Drug 1062 1083	vitamin K antagonists
T20	Drug 1087 1091	NOAC
T21	Condition 1132 1142	PE episode
T22	Drug 1151 1170	antiplatelet agents
T23	Negation 1171 1177	except
T24	Negation 1111 1116	other
T25	Qualifier 1126 1131	index
T27	Drug 1178 1198	acetylsalicylic acid
T28	Multiplier 1211 1223	=100 mg/day;
T31	Condition 1225 1240	Active bleeding
T32	Observation 1262 1275	bleeding risk
T33	Qualifier 1250 1261	significant
T34	Condition 1283 1305	gastrointestinal ulcer
T35	Condition 1307 1326	malignant neoplasms
T36	Condition 1328 1336	injuries
T37	Procedure 1347 1356	surgeries
T38	Qualifier 1364 1369	brain
T39	Qualifier 1371 1382	spinal cord
T40	Qualifier 1386 1390	eyes
T42	Condition 1399 1421	intracranial bleedings
T43	Condition 1442 1459	esophagus varices
T44	Condition 1461 1470	aneurysms
T45	Condition 1502 1525	vascular abnormalities)
T46	Qualifier 1489 1501	intracranial
T47	Qualifier 1474 1485	intraspinal
T50	Device 1527 1550	Artificial heart valves
T51	Drug 1579 1592	anticoagulant
T52	Condition 1594 1613	Renal insufficiency
T53	Measurement 1619 1649	estimated creatinine clearance
T54	Value 1650 1667	<30 ml/min/1.73m2
T55	Condition 1669 1690	Chronic liver disease
T56	Measurement 1696 1712	aminotransferase
T57	Value 1720 1781	two times or more above the local upper limit of normal range
T58	Drug 1820 1848	inhibitors of P-glycoprotein
T60	Drug 1854 1866	ketoconazole
T61	Drug 1868 1879	cyclosporin
T62	Drug 1881 1893	itraconazole
T63	Drug 1897 1908	dronedarone
T64	Post-eligibility 1910 1986	Unwillingness or inability to adhere to treatment or to the follow-up visits
T65	Observation 1988 2003	Life expectancy
T66	Value 2004 2022	less than 6 months
